The rapid spread of the coronavirus disease 2019 (COVID-19) pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection highlights an urgent need …

Li et al.(1) recently report the discovery of 16 Food and Drug Administration–approved drugs
as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) main protease (M pro) …

As an essential enzyme of SARS-CoV-2, main protease (MPro) triggers acute toxicity to its
human cell host, an effect that can be alleviated by an MPro inhibitor. Using this toxicity …

As an essential enzyme of SARS-CoV-2, the pathogen of COVID-19, main protease (MPro)
triggers acute toxicity to its human cell host, an effect that can be alleviated by an MPro …

For rapid discovery of novel SARS-CoV-2 main protease (Mpro) inhibitors, an optimized
fluorescence resonance energy transfer (FRET)-based high-throughput screening (HTS) …

Traditional Chinese medicine has made contributions to the treatment of coronavirus
disease 2019 (COVID-19) because of its favorable efficacy, such as Huashi Baidu decoction …

Except remdesivir, no specific antivirals for SARS-CoV-2 infection are currently available.
Here, we characterize two small-molecule-compounds, named GRL-1720 and 5h …

Abstract Background/Aim SARS‐CoV‐2 is one of the coronavirus families that emerged at
the end of 2019. It infected the respiratory system and caused a pandemic worldwide …

The main protease (Mpro) plays a pivotal role in the replication of severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) and is considered a highly conserved viral target …

The severe acute respiratory syndrome coronavirus 2 main protease (SARS-CoV-2-Mpro)
plays an essential role in viral replication, transcription, maturation, and entry into host cells …